盆腔外照射放疗对骨密度的影响:一项3期随机对照试验的二次分析
该研究为随机双盲安慰剂对照试验的探索性分析,纳入1407例接受ADT的非转移性前列腺癌患者,31%(447例)有盆腔外照射放疗史。既往盆腔放疗与安慰剂组骨密度显著改善0.54%相关,与地舒单抗组骨密度非显著下降0.04%相关(交互P=0.007)。两组临床骨折发生率无显著差异(5.8% vs 5.2%,P=0.42)。
要点
- 既往盆腔放疗患者与无放疗患者临床骨折发生率无显著差异(5.8% vs 5.2%,P=0.42)。
- 盆腔放疗与安慰剂组骨密度显著改善0.54%相关,与地舒单抗组非显著下降0.04%相关(交互P=0.007)。
- 两组间腰椎和全髋骨密度百分比变化无显著差异(P=0.65和P=0.39)。
核心结论
- 未发现足够证据表明盆腔外照射放疗对地舒单抗改善骨密度百分比变化的疗效有不良影响,临床骨折发生率约5%。
研究设计与样本
- 随机双盲安慰剂对照试验的探索性二次分析,纳入1407例 eligible 非转移性前列腺癌患者,31%(447例)有既往盆腔外照射放疗史。
- 患者年龄≥70岁或<70岁且骨密度低(T值<-1)或骨质疏松性骨折,已接受ADT≥12个月,随机接受地舒单抗或安慰剂每6个月一次共3年。
- 骨密度在基线及第1、3、6、12、24、36个月测量,采用多变量线性混合效应模型分析。
主要发现
- 既往盆腔放疗患者与无放疗患者任何临床骨折发生率无显著差异(5.8% vs 5.2%,P=0.42)。
- 既往盆腔放疗与安慰剂组骨密度显著改善0.54%(95%CI 0.05-1.02)相关。
- 既往盆腔放疗与地舒单抗组骨密度非显著下降0.04%(95%CI -0.47至-0.35)相关(交互P=0.007)。
- 两组间腰椎骨密度百分比变化的放疗效应无显著差异(P=0.65)。
- 两组间全髋骨密度百分比变化的放疗效应无显著差异(P=0.39)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pelvic radiation therapy may lead to decreased bone mineral density (BMD) and increased risk of fracture that could be of particular concern in patients with prostate cancer who also receive androgen deprivation therapy (ADT). We performed an exploratory analysis of a randomized, double-masked, placebo-controlled trial to determine whether exposure to prior pelvic external beam radiation therapy (XRT) affects BMD and risk of fracture in patients with prostate cancer treated with ADT. METHODS AND MATERIALS: Patients with nonmetastatic prostate cancer aged ≥70 years or <70 years with low BMD (T-score < -1) or osteoporotic fracture who had been receiving ADT for ≥12 months were randomly assigned to receive densoumab or placebo every 6 months for 3 years. BMD was measured at baseline and at months 1, 3, 6, 12, 24, and 36. We applied multivariable linear mixed-effects models with an interaction term between the treatment arm and exposure to prior pelvic XRT to evaluate differential XRT effect on percent BMD change between the 2 treatment arms. RESULTS: Among 1407 eligible patients, 31% (n = 447) received prior pelvic XRT. There was no significant difference in any clinical fractures among patients with (5.8%, 26 of 447) or without (5.2%, 50 of 960) prior pelvic XRT (P = .42). Prior pelvic XRT was associated with a significant (0.54%) improvement in BMD (95% CI, 0.05-1.02) in the placebo group and a nonsignificant (0.04%) decline in BMD (95% CI, -0.47 to -0.35) in the denosumab group (interaction P = .007). There was no significant difference in pelvic XRT effect on percent BMD change in the lumbar spine (P = .65) or total hip (P = .39) between the 2 treatment groups. CONCLUSIONS: We did not find sufficient evidence to suggest any detrimental effect of pelvic XRT on the treatment effect from denosumab on percent BMD change, with only an approximately 5% incidence of clinical fractures.
引用
- Roy S, Malone S, Sun Y, et al. Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase 3 Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37924987. doi:10.1016/j.ijrobp.2023.10.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。